How much funding has Prellis Biologics raised?

Prellis Biologics has raised $49.5M in total funding, most recently a Series C round.

Who are Prellis Biologics's investors?

Prellis Biologics's investors include Celesta Capital, Avidity Partners.

When was Prellis Biologics founded?

Prellis Biologics was founded in 2016.

Where is Prellis Biologics headquartered?

Prellis Biologics is headquartered in San Francisco, California, United States.

What industry is Prellis Biologics in?

Prellis Biologics operates in Healthcare, Biotech.

How many employees does Prellis Biologics have?

Prellis Biologics has 11-50 employees.

Prellis Biologics

Harnessing human diversity and AI to build next-generation medicines

San Francisco, United States · Founded 2016 · $49.5M raised

Healthcare

Biotech

Headquarters: San Francisco, California
Employees: 11–50
Founded: 2016
Business Model: B2B

Website: prellisbio.com
Total Funding: $49.5M
Last Round: $35.0M Series CAug 2022
Rounds: 2

About

Prellis Biologics is a pre-IPO biotech company that harnesses AI and human immune diversity to develop next-generation antibody therapeutics. Its EXIS (Externalized Immune System) platform combines holographic bioprinting, fully human antibody discovery, and tightly integrated machine learning to identify antibody candidates from the full human immune repertoire with unparalleled speed and precision. The company partners with pharmaceutical companies to advance drug discovery across metabolic disease, inflammation, and oncology.

Summary

Prellis Biologics is a Healthcare company based in San Francisco, United States, founded in 2016. It has raised $49.5M in total across 2 rounds, most recently a $35.0M Series C round in Aug 2022. Investors include Celesta Capital and Avidity Partners.

LinkedIn X (Twitter)